NTRK1 and gastrointestinal stromal tumor: Sunitinib, a receptor tyrosine kinase inhibitor, and chemotherapeutic agent is used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) is a hybrid of isatin and pyrrole pharmacophores.